Asset profile
DISC-0974
Monoclonal antibody
Evidence outlook · lead readout
NCT05745883 · Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05745883: The study randomized participants to DISC-0974 or placebo with full blinding, but its primary endpoints are safety measures rather than a disease outcome, and no results have been posted, so its ultimate finding cannot yet be assessed.
This is an interim readout from the single-ascending-dose cohorts, not the completed trial.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.